Compare ASTC & ASBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASTC | ASBP |
|---|---|---|
| Founded | 1984 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.4M | 12.4M |
| IPO Year | 2020 | 2021 |
| Metric | ASTC | ASBP |
|---|---|---|
| Price | $6.87 | $8.32 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 27.3K | ★ 28.4K |
| Earning Date | 09-25-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2600.00 | N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $1,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $27.36 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.92 | $0.05 |
| 52 Week High | $68.85 | $9.50 |
| Indicator | ASTC | ASBP |
|---|---|---|
| Relative Strength Index (RSI) | 47.43 | 47.66 |
| Support Level | $6.80 | $7.88 |
| Resistance Level | $7.76 | $9.37 |
| Average True Range (ATR) | 0.55 | 0.56 |
| MACD | 0.02 | -0.04 |
| Stochastic Oscillator | 45.69 | 28.85 |
Astrotech Corp is a science and technology company. It creates, operates and scales businesses through its subsidiaries and technology platforms, including space-related technology, instrumentation, mass spectrometry, gas chromatography, process-control and environmental analysis technologies. It is evaluating opportunities to identify, develop and commercialize technologies with potential applications in space, defense, industrial, environmental, quantum computing, AI, semiconductor materials, lunar infrastructure and related markets. Its products include Tracer 1000 ETD, tracer 1000 NTD, Labrador HHGC, Fenceline GC, AgLab 1000-D2, among others. It operates in single segment.
Aspire Biopharma Holdings Inc is an early-stage biopharmaceutical company focused on developing and commercializing novel sublingual drug delivery technologies. The company is mainly engaged in advancing patent-pending formulations designed to enable rapid absorption of drugs, initially targeting high-dose aspirin products for cardiovascular and pain management applications. Its technology aims to improve efficacy and response time by bypassing the gastrointestinal tract through sublingual delivery.